Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

Paris: Sanofi has completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a ...

Sanofi’s acquisition of Vigil Neuroscience involves purchasing the company for $8 per share in cash, along with an additional $2 in contingent value rights, pending the commercial success of ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

May 22, 2025 Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline Sanofi will acquire Vigil Neuroscience , a clinical-stage biotech company in a $470 million ...

Japan’s Nippon Steel is set to finalize its acquisition of U.S. Steel for $55 per share, following a green light from ...

In its most recent quarter, Nvidia delivered blockbuster results, driven by full-scale production of its Blackwell GPUs and ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €110.00. The company’s shares closed yesterda ...

In a report released today, Benjamin Jackson CFA from Jefferies maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €120.00. The company’s sh ...

The latest price target for Vigil Neuroscience (NASDAQ:VIGL) was reported by JMP Securities on May 22, 2025. The analyst firm set a price target for $0.00 expecting VIGL to fall to within 12 ...